Effect of dapagliflozin on the serum metabolome in patients with type 2 diabetes mellitus.

ABSTRACT:

Objectives

SGLT-2 inhibitors have been shown to exert cardio- and renoprotective actions. We aimed to investigate the underlying mechanisms using ¹H-NMR based metabolomics in patients with type-2 diabetes mellitus who received dapagliflozin.

Methods

50 patients with type 2 diabetes mellitus, inadequately controlled on metformin monotherapy (HbA1c > 7%) received dapagliflozin for 3 months and 30 matched patients received insulin degludec for 3 months. Clinical and laboratory values, as well as ¹H-NMR based metabolomics were assessed before treatment and after completion of 3 months of treatment.

Results

Dapagliflozin reduced weight, body mass index, systolic and diastolic blood pressure significantly. Using ¹H-NMR based metabolomics, th

SUBMITTER: Filippas-Ntekouan S 

PROVIDER: S-EPMC11649604 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature